ScholarIQanswers from OpenAlex & ORCID
Mark A. Watson
ResearcherPublications, citations & collaboration network
Mark A. Watson is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark A. Watson have?
ScholarIQindexed works
Mark A. Watson has 313 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark A. Watson have?
ScholarIQcitation count
Mark A. Watson has 30,215 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark A. Watson?
ScholarIQh-index
Mark A. Watson has an h-index of 72 in OpenAlex.
What is the i10-index of Mark A. Watson?
ScholarIQi10-index
Mark A. Watson has an i10-index of 132 in OpenAlex.
What is the ORCID of Mark A. Watson?
ScholarIQorcid
The ORCID for Mark A. Watson is on the source record.
What is the OpenAlex record for Mark A. Watson?
ScholarIQopenalex
The OpenAlex for Mark A. Watson is on the source record.
What are the most-cited papers on Mark A. Watson?
ScholarIQmost cited works
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein, Sam Ng, Lin Li, Robert J. Crowder, Jacqueline Snider, Karla V. Ballman, Jason D. Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson